Table 1.
Patient characteristics and clinical parameters used to assess vedolizumab outcomes.
| Combined (n = 88) | CD (n = 44) | UC (n = 44) | p-Value | |
|---|---|---|---|---|
| Age (median (IQR)) | 39.5 [31.0, 53.3] | 41.0 [29.0, 59.3] | 38.00 [31.0, 50.3] | 0.251 |
| Gender = Male (%) | 30 (34.1) | 13 (29.5) | 17 (38.6) | 0.5 |
| Race (%) | 0.68 | |||
| Asian | 6 (6.8) | 2 (4.5) | 4 (9.1) | |
| Black | 11 (12.5) | 6 (13.6) | 5 (11.4) | |
| Caucasian | 71 (80.7) | 36 (81.8) | 35 (79.5) | |
| Disease Duration (years) | 10.5 [5.1, 17.3] | 11.5 [5.7, 21.8] | 8.93 [5.1, 13.0] | 0.069 |
| Location of Disease | <0.001 | |||
| Colonic | 60 (68.2) | 17 (38.6) | 44 (100) | |
| Proximal | 9 (10.2) | 9 (20.5) | 0 (0.0) | |
| Colonic + Proximal | 19 (21.6) | 18 (40.9) | 0 (0.0) | |
| # Prior Therapies | 1.0 [1.0, 2.0] | 1.0 [1.0, 2.25] | 1.0 [1.0, 2.0] | 0.077 |
| # Prior Surgeries | 1.0 [1.0, 2.0] | 1.0 [1.0, 2.0] | 2.0 [1.5, 2.5] | 0.487 |
| # Baseline Endoscopic Score (UC = UCEIS, CD = SES-CD) (median [IQR]) | 15.00 [12.25, 23.25] | 6.00 [3.00, 8.75] | N/A |
Data shown in n (%) or median (IQR) unless otherwise stated. UCEIS: Ulcerative Colitis Endoscopic Index of Severity score. SES-CD: Simple Endoscopic Score for Crohn’s disease. Proximal includes small bowel +/− gastric disease. Bolded p value represents statistically significant findings.